Categories AlphaGraphs, Earnings, Health Care

Earnings preview: Amarin likely to deliver strong Q4 results

Amarin Corporation (AMRN) is scheduled to report earnings results for the fourth quarter of 2018 on Wednesday, February 27, before the market opens. Analysts expect the company to report a loss of $0.08 per share on revenues of $74.4 million for the recently ended quarter.

Amarin has a mixed track record in terms of meeting earnings estimates and over the past four quarters, the company has missed expectations twice. The company’s primary product, Vascepa, has grown consistently over the past nine months and this momentum will continue in the fourth quarter as well. New approvals might also help in driving sales growth going forward.

In November, Amarin published positive results pertaining to the REDUCE-IT study, which evaluated the cardiovascular risk reduction potential of Vascepa, thereby giving the company potential for significant benefits through the affordably-priced drug. However, higher costs are likely to hurt Amarin in the fourth quarter as the company continues to implement strategic initiatives for business growth.

amarin fourth quarter 2018 earnings preview

Last month, Amarin published preliminary results for 2018 and provided its outlook for 2019. The company expects record revenues for the fourth quarter and full year of 2018 in the ranges of $72 million to $76 million and $224 million to 228 million, respectively. The full-year results represent an increase of 24-26% over 2017.

The quarterly and full-year revenue numbers predominantly reflect US sales driven by increased prescriptions for Vascepa. For 2019, Amarin expects total revenue of about $350 million, reflecting an increase of more than 50% from 2018, mostly from US sales of Vascepa.

Amarin’s stock gained 14% on Friday on rumors that Novartis (NVS) might be interested in an acquisition. However, Novartis declined to offer any comment on the issue. Similarly, last month, Amarin’s stock surged on rumors that Pfizer (PFE) was looking to acquire the company. There have been no further reports on the outcome of this matter.

The majority of analysts have rated Amarin as a Strong Buy while none have rated it Sell. Over the past six months, the stock has gained 588% while over the past month, it has climbed 7%. The stock was down 3.6% in morning hours on Monday.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top